Parikshit Somani and the Four-Year Ban: Trimetazidine, Contamination Claims and the Burden of Proof in Lower-Tier Tennis

The International Tennis Integrity Agency, headquartered in London, released a short statement on a Wednesday. Buried in it was a name most tennis followers in Southeast Asia have never heard: Parikshit Somani, a 26-year-old Indian doubles specialist whose career-high ranking reached No. 256. He has been suspended for four years, a ban running until September 2029.

The number is not the most telling part of the release. The three phrases the tribunal used to describe Somani's explanation are: scientifically implausible, highly speculative, and unconvincing. Those phrases open a door onto the architecture of modern anti-doping, a structure in which a player ranked No. 256 must prove his innocence with his own resources.

Somani tested positive for trimetazidine at a lower-tier event in Astana, Kazakhstan. The banned heart medication is the same molecule that appeared in two far larger cases: Kamila Valieva, the Russian figure skater banned for four years after the scandal at the 2026 Beijing Olympics, and Sun Yang, the Chinese swimming star who served a three-month suspension in 2026 for the same substance.

The economy beneath the ranking

Beneath the ATP and Challenger Tours sits the ITF World Tennis Tour, where events are named for their total prize pools: M15, M25, W15, W25. An M15 offers 15,000 US dollars split across a 32-player draw. The singles champion takes home roughly 2,000 dollars before tax. Doubles is thinner still, with the winning pair dividing a few hundred dollars.

For a doubles specialist at that level, the career is an exercise in cost accounting. Flights, hotels, food, physiotherapy, a coach if there is one, practice court fees before the event. Flying from India to Kazakhstan is not cheap, and Astana in winter is not a place anyone lingers. Based on my experience tracking matches at lower-tier ITF events across Asia, most players ranked outside the top 300 earn less in a year than they spend. They compete on savings, family support, or national federation grants.

That economic backdrop matters. A player at that level, called for a urine sample after a first-round doubles match on an indoor court in Astana, answers the doping officer's questions in exactly the same way Novak Djokovic would. By the time the case reaches a tribunal, the two are no longer equal.

What trimetazidine does

Trimetazidine is an anti-anginal drug developed by a French pharmaceutical company and sold under many brand names worldwide. Its mechanism is unusual. Heart muscle normally draws most of its energy from burning fatty acids, an oxygen-hungry process. Trimetazidine inhibits the enzyme 3-KAT, a link in the fatty acid oxidation chain, pushing the heart toward glucose oxidation, which delivers more energy per unit of oxygen consumed. For a patient with narrowed coronary arteries, that is a genuine clinical benefit. For an athlete trying to recover between sets, it is a different kind of benefit.

The substance was added to the World Anti-Doping Agency's Prohibited List effective January 1, 2026, under category S4, hormone and metabolic modulators. The crucial technical point: trimetazidine has no permitted threshold. WADA had to publish a 1 microgram per millilitre threshold for meldonium after criticism over the 2026 wave of positives. For trimetazidine, no such threshold exists. Its presence at any measurable concentration constitutes a violation.

Its pharmacokinetics complicate matters further. The plasma half-life is roughly seven hours, and most of the drug is excreted unchanged in urine. A single dose leaves traces within a detection window of only a few days. That means a positive result usually corresponds to use very close to the sample collection date, not an error from weeks earlier. It is precisely why environmental contamination arguments are hard: the window is narrow, and the error has to fit inside it exactly.

Trimetazidine is not approved in the United States, but it is common in Russia, Eastern Europe, China, and India, where it is widely prescribed under several trade names for cardiac patients. This detail matters for Somani: he comes from a country where the drug sits in thousands of household medicine cabinets.

Three defences, one molecule

Valieva's sample was collected on December 25, 2026, at the Russian national championships in St Petersburg. The Stockholm laboratory reported the positive result on February 8, 2026, after she had finished the team event in Beijing and helped the Russian Olympic Committee to the top of the standings. She was still allowed to compete in the singles. The case became a global media crisis lasting days. Only on January 29, 2026, did the Court of Arbitration for Sport issue a final ruling: four years from the sample date, with all results from that date disqualified.

Valieva's legal team built its argument around her grandfather, who took heart medication containing trimetazidine. The lawyers raised hypotheses about a strawberry dessert, about a chopping board, about indirect transmission routes through the family kitchen. The CAS panel listened, acknowledged the theoretical possibility, and concluded that the source of the prohibited substance had not been established.

Sun Yang's sample was collected on May 17, 2026, at the Chinese national championships. He tested positive for trimetazidine and received a three-month suspension. The timing is notable: the substance had been on the WADA list for only a few months, and the Chinese side explained that the swimmer took the drug to treat angina and muscle pain. Four years later, Sun Yang entered an entirely different case, the 2026 sample destruction affair, which produced an eight-year ban later reduced to four years and three months.

Three cases, one molecule, three ecosystems with radically different resources. Valieva had a national sports apparatus behind her. Sun Yang had a sports system with close medical oversight. Somani had a family and a doubles career at the bottom of international tennis.

The science of contamination claims

Sports tribunals do not judge by intuition. They judge by standards of proof. Under the 2026 World Anti-Doping Code, an athlete seeking to eliminate or reduce a sanction on grounds of no fault or no significant fault must establish, on the balance of probabilities, how the prohibited substance entered the body. It is not enough to say it could have happened. The athlete must show how it did.

In practice, a successful contamination argument usually has four components. First, an identified product: a supplement container, a cut of meat, a pill. Second, an analytical result showing that product contains the prohibited substance. Third, a plausible dose calculation explaining the concentration measured in the urine sample. Fourth, a timeline fitting the detection window of that substance.

The most famous successful contamination cases follow this structure. The clenbuterol cases in Mexico and China were accepted because there was contaminated beef, national monitoring data on residue rates in food, and a specific food sample to compare. Contaminated supplement cases succeed when the container survives, the lot number is readable, and the laboratory finds the prohibited substance at concentrations that could only come from manufacturing rather than intent.

The claim that a family member's medicine got into the food belongs to a harder category altogether. There is no product to test. No lot number. No concentration to work backwards from. What remains is a story, and a story in a hearing room is not evidence.

The tribunal's three adjectives reflect exactly that gap. Scientifically implausible, because no transmission route could be shown to produce the measured concentration. Highly speculative, because every link in the chain was an assumption. Unconvincing, because an assumption cannot substitute for a measurement.

There is data that does not need to shout; it only needs someone patient enough to read it. Here, the silent data is the absence of data.

The burden of proof is an economic variable

An athlete trying to prove a contamination source must do things that cost money. Hire a lawyer who understands international sports law. Hire a pharmacokinetics expert to reconstruct the concentration model. Pay for additional testing on samples and on the suspected product. Pay for interpreters, travel to hearings, and time. Time, for a professional athlete, is prize money not earned and ranking points bleeding away.

Compare the three trimetazidine cases. Valieva had legal support from her national federation and the sports apparatus; her hearings stretched over years and generated an enormous documentary record. Sun Yang had a sports system willing to fund an elaborate defence. Somani presented his explanation at a hearing in August, and the panel found it did not hold.

I am not saying Somani is innocent. I do not have the data to say that. What I am saying is different: a system that claims to judge every athlete by the same standard, while the cost of meeting that standard varies by a factor of hundreds between cases, is operating on formal fairness.

Rebellion does not have to be loud; sometimes it is quietly rearranging the numbers. Line up the three trimetazidine cases along a financial axis instead of a geographic one, and the picture changes completely.

One case casting a shadow over another

The ITIA release chose to highlight the similarity to the Valieva case. That is a reasonable editorial choice: readers need an anchor to understand what trimetazidine is. It also creates a side effect. When two names appear side by side, readers tend to transfer the full prejudice attached to the more famous case onto the lesser one. The Valieva affair left the public with a mental template: Russian athlete, state doping system, grandfather's medication, four years. When that template activates, judgement of Somani becomes faster and coarser.

In my profession, this is the most common error. I once mispronounced Luka Modric's name three times in the first half of the 2026 World Cup semi-final in Russia and was heavily criticised online. I retreated to my hotel, shut the door for two days, then watched all five Croatia matches to write a portrait of his invisible work: more than ninety kilometres covered across the tournament, fourteen chances created from passes the cameras usually miss. The Croatian outlet Sportske Novosti shared the piece. Since then I have followed one rule: three sources to confirm a pronunciation, and never let a famous name obscure a lesser one.

The same principle applies here. Sharing a substance does not make two cases one. The tribunal in Somani's case was not judging Russia. It was judging an explanation.

Who is a four-year ban designed for

Under the 2026 Code, the standard sanction for a non-specified substance is four years. Trimetazidine falls into that class. The penalty is not tailored to individuals; it is designed for a system, to ensure the cost of cheating exceeds the potential gain.

For a tennis star, four years is a career death sentence. For a 26-year-old ranked No. 256 in doubles, it is more than that. It is the entire remaining span of peak physical capacity before reflexes and recovery decline. In four years, such a player loses all ranking, all accumulated points, coaching relationships, and eligibility. The ban forbids him from competing, coaching, or attending any event organised by the sport's governing bodies, the Grand Slams, and national federations.

Analysts often discuss deterrence without noting that deterrence is unevenly distributed. For someone with a short career at the top, four years is a deep cut. For someone with long-term sponsorship and brand equity, four years can be renegotiated into a relaunch. At the lower tier, four years is a full stop with no sequel.

ITIA and the architecture of enforcement

The ITIA was created to centralise tennis's anti-corruption and anti-doping work, operationally separate from the International Tennis Federation. Structurally, that is sensible: an independent body handling investigation and prosecution, with an independent tribunal issuing rulings. In resource terms, it must oversee a system of tens of thousands of athletes across every continent.

The athlete population it polices forms a very sharp pyramid. At the peak, a few hundred players live on prize money and sponsorship. In the middle, a few thousand make a living. At the base, tens of thousands pay to compete. Every one of them must file whereabouts information, can be tested at any time, and faces the same penalty framework.

That is the structure I always want to examine closely whenever a sanction is announced. When a ban falls on a player without money, it does not merely end a career. It signals to those above that the system works, that testing is serious, that no one is above the rules. And it signals to those below something entirely different: that your greatest risk is not your conduct, but your inability to afford an explanation of it.

Both signals coexist. A system can be serious and unjust to its weakest participants at the same time.

The empty track and sociological questions

In 2026, when the pandemic wiped out the calendar, I left Hanoi for Haiphong and reopened my master's thesis in sociology. I began writing a weekly newsletter about a legendary race, placing it in the social context that produced it. By year's end it had 3,200 subscribers, mostly coaches who had lost their training grounds.

The empty track is where I hear my own footsteps most clearly. Since then, every piece I write begins with a sociological question. Why does this race exist? What does it reveal about the era that produced it?

Applied to Somani: why does a doubles player ranked No. 256 become the focus of an international news item? The answer is not about him. It lies in the fact that the anti-doping system needs cases at every tier to demonstrate its universality. Those at the bottom usually pay the cheapest price for that need.

Judgement

I expect the Somani case to change nothing. It is too small, the subject too obscure, the story too difficult to compress into a short bulletin. The ban will run until September 2029, and by then most tennis followers will have forgotten the name.

One thing is worth keeping. Whenever a system declares that it treats everyone equally, check what it costs to enjoy that equality, and who pays. For a 26-year-old in Astana, the cost may be an entire career.

Sport is a common language because it lets people of different tongues, nationalities, and circumstances compete on the same baseline. But a common language only holds value when everyone learns it from the same dictionary. If the dictionary is written for those who can afford it, the language was split in two long ago; most of us simply never read that far.